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TNP11-OVA administration in TNP-IgE
Tg mice may strongly induce the gen-
eration and secretion of a-MSH from
mast cells. In addition, NC/Nga mice,
which develop AD-like dermatitis un-
der conventional conditions, displayed
an increase of the plasma levels of a-
MSH and an increase of the expression
of Mc1r and Mc5r in skin (Hiramoto
et al., 2009). This report in NC/Nga
mice indicated a similar result to ours,
which is an increase of the expression
of Mc1r and Mc5r on the ears in TNP-
IgE Tg mice after TNP11-OVA adminis-
tration.
In conclusion, we identified the nine
GPCR genes that are highly expressed
just before IgE-mediated chronic in-
flammation in TNP-IgE Tg mice. The
ligands for MC1R and MC5R showed
inhibitory effects on IgE-mediated
chronic allergic inflammation. This
result indicates that MC1R and MC5R
are involved, at least partially, in the
regulation of IgE-mediated chronic in-
flammation. We previously showed that
basophils are crucially involved in the
third-phase ear swelling in TNP-IgE Tg
mice (Mukai et al., 2005). To our
knowledge, there is no available in-
formation about the expression of Mc1r
and Mc5r on basophils; therefore, we
assume that Mc1r and Mc5r indirectly
inhibit IgE–basophil-mediated chronic
inflammation. Further analysis of the
mechanism of the other candidate genes
could lead to the discovery of unknown
mechanisms of IgE-mediated chronic
allergic inflammation and a therapeutic
target for treating chronic allergic in-
flammation.
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TO THE EDITOR
Psoriatic skin contains more nerve
fibers (Naukkarinen et al., 1989), has
increased levels of sensory nerve–der-
ived calcitonin gene-related peptide
(CGRP) and substance P (SP; Chan
et al., 1997; Jiang et al., 1998), and
psoriasis disease severity can be
exacerbated by stress (Griffiths and
Richards, 2001), possibly by increasing
cutaneous nerve numbers and SP and
CGRP expression (Joachim et al., 2007;
Remrod et al., 2007). The clinical
observation that psoriasis undergoes
remission following loss of innervation,
nerve function, or nervous system
injury (Dewing, 1971; Perlman, 1972;
Farber et al., 1990; Stratigos et al.,
1998; Joseph et al., 2005) further
supports a role for the nervous system
in psoriasis pathogenesis; however, the
Abbreviations: BoNT-A, botulinum neurotoxin A; CGRP, calcitonin gene-related peptide ; DC, dendritic
cell; PASI, psoriasis area and severity index; SP, substance P
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neural-mediated mechanisms underly-
ing disease resolution in these cases
have not been explored. Recent work
by our group identified increases in
cutaneous nerve fibers and nerve-de-
rived SP and CGRP in the KC-Tie2
murine model of psoriasiform dermati-
tis, providing an experimental para-
digm to explore neural contributions to
psoriasis pathogenesis. Surgical elim-
ination of the cutaneous nerves in KC-
Tie2 mouse dorsal skin resulted in a
30% improvement in acanthosis, a
40% decrease in CD11cþ dendritic
cells (DCs), and a 30% decrease in
CD4þ T cells. These outcomes were SP
and CGRP dependent, as reconstitution
of SP and CGRP in denervated KC-Tie2
skin prevented improvement in the
phenotype and inhibition of SP and
CGRP in innervated KC-Tie2 skin
recapitulated the findings elicited
by experimental denervation in a sen-
sory neuropeptide–specific manner
(Ostrowski et al., 2011). These findings
provide insight into potential mechan-
isms underlying clinical reports
of disease improvement following
Saline
H
&E
CD
4
CD
11
c
BoNT-A
100 μm
Figure 1. Botulinum neurotoxin A (BoNT-A) improves skin disease severity in KC-Tie2 mice.
Representative images of hematoxylin and eosin (H&E)-stained (a, b), and CD11c- (c, d) and CD4- (e, f)
immunostained back skin of KC-Tie2 animals at 6 weeks after a single intradermal injection of either
saline (a, c, e) or BoNT-A (b, d, f; Dysport, 9 units per kg). Bar¼ 100mm.
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Figure 2. Acanthosis, CD11cþ dendritic cells (DCs), and CD4þ T-cell numbers decrease following botulinum neurotoxin A (BoNT-A) injection. Acanthosis
(epidermal thickness; in mm), CD11cþ DCs, and CD4þ T-cell numbers are presented for saline- and BoNT-A-injected skin of individual animals at 2 (n¼ 5)
and 6 weeks (n¼ 6). Acanthosis improves in BoNT-A compared with saline-injected skin at 2 weeks (B17% decrease, P¼ 0.031) and 6 weeks (B25% decrease;
P¼ 0.011). Dermal CD11cþ DC numbers decrease in BoNT-A- compared with saline-injected skin at 2 weeks (29% decrease; P¼ 0.002) and 6 weeks
(38% decrease; Po0.0001). CD4þ T-cell numbers decrease significantly in BoNT-A- compared with saline-injected skin at 2 weeks (24% decrease; P¼ 0.017)
and 6 weeks (34% decrease; Po0.002). All data were analyzed using paired Student’s t-test.
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nervous system injury and identify key
roles for nerve-derived SP and CGRP in
sustaining chronic psoriasiform skin
inflammation.
Botulinum neurotoxins of various
serotypes function by inhibiting the
exocytosis of neurotransmitters from
nerve endings. Botulinum neurotoxin
A (BoNT-A, known commonly by the
trade names BOTOX, Dysport, and
Xeomin) does so by cleaving the
SNAP25 protein, and is best known
for its capacity to inhibit acetylcholine
release in neuromuscular junctions and
at the neurovascular interface, and
therefore is often used to treat glabellar
lines, hemifacial spasm, cervical dysto-
nia, blepharospasm, hyperhidrosis,
and Raynaud’s disease. However,
BoNT-A also inhibits nerve-derived
release of CGRP and SP and can be
used for treating pain syndromes and
potentially neurogenic inflammation
(Meng et al., 2007; Carmichael et al.,
2010). This is particularly significant
and provides mechanistic insight
into the recent unpublished observation
of psoriatic plaque remission in a
patient injected with BoNT-A for the
treatment of upper limb spasticity re-
lated to stroke (J Andrews, personal
communication), and the subjective
clinical observation of disease improve-
ment in inverse psoriasis following
BoNT-A administration (Zanchi et al.,
2008).
This study sought to investigate
whether one intradermal injection of
BoNT-A into KC-Tie2 mouse skin
would provide similar levels of im-
provement in skin disease as surgical
denervation and/or chemical inhibition
of SP and CGRP. Adult KC-Tie2 mouse
dorsal skin was intradermally injected
with BoNT-A (Dysport; 9 units kg–1
100 ml–1) and saline (100 ml volume) in
anatomically separate locations; the
regions were marked and images were
taken to ensure that the same locations
were harvested for analyses. After 2
(n¼5) or 6 weeks (n¼6), mice were
killed, and BoNT-A- and saline-
injected skin was harvested and
processed for histological and immu-
nostaining analyses as described
previously (Ostrowski et al., 2011).
All animal protocols were approved
by the Case Western Reserve Univer-
sity institutional animal care and use
committee.
Dorsal skin injected once with
BoNT-A showed significant improve-
ment in acanthosis compared with
saline-injected skin at 2 weeks (B17%
decrease; P¼0.031) and 6 weeks
(B25% decrease; P¼0.011; Figures
1a and b and 2). Dermal DC infiltration
was also significantly reduced, evi-
denced by a significant decrease in
the number of dermal CD11cþ DCs in
BoNT-A-injected skin compared with
saline-injected skin (Figures 1c and d
and 2) at 2 weeks (29% decrease;
P¼0.002) and 6 weeks (38% decrease;
Po0.0001). CD4þ T-cell numbers also
decreased significantly in BoNT-A-in-
jected skin compared with saline-in-
jected skin (Figures 1e and f and 2) at
2 weeks (24% decrease; P¼0.017) and
6 weeks (34% decrease; Po0.002). The
number of F4/80þ macrophages and
CD8þ T cells did not differ between
BoNT-A- and saline-injected skin, nor
were any changes observed for dermal
angiogenesis (blood vessel number or
size) at either of the time points
examined (not shown).
These findings demonstrate a sig-
nificant improvement in psoriasiform
skin inflammation and epidermal hy-
perplasia following one intradermal
injection of BoNT-A, and identify
decreases in infiltrating CD4þ T cells
and CD11cþ DCs that occur conco-
mitant with the improvement in
acanthosis. These findings are similar
to those we previously reported, and
the percent improvement for each
outcome was comparable to that ob-
served following surgical elimination
of the cutaneous nerves as well as
following 4 weeks of CGRP and SP
inhibition (Ostrowski et al., 2011), and
suggest that BoNT-A might serve as a
useful psoriasis therapeutic agent.
However, the use of BoNT-A as mono-
therapy for patients with high PASI
(psoriasis area and severity index)
scores (450) is not a practical ap-
proach. Nevertheless, in some psoria-
sis patients, recalcitrant plaques
remain, even after treatment with
strong systemic and biological therapies
such as tumor necrosis factor-a
(TNF-a) inhibitors. The persistence of
some plaques may be explained by the
local microenvironment within the
tissue combined with signals yet
unaccounted for that have strong
proinflammatory effects, such as
nerve-derived SP and CGRP. Our pre-
vious results (Ostrowski et al., 2011)
identified these neuropeptides as
necessary to sustain and exacerbate
tissue hyperproliferation, and suggest
that the presence of nerves and
their derived proteins have critical
roles in the cascade of events that
sustain inflammation and acanthosis.
The ability to interfere with cutaneous
nerve signaling presents an opportunity
to address recalcitrant plaque psoria-
sis; thus, BoNT-A may serve as a
supplemental therapeutic approach
to otherwise successful topical or
biological regimens. The current data
validate this idea and demonstrate
that a single intradermal injection
of BoNT-A, a known inhibitor of
CGRP/SP release, leads to significant
improvement in disease severity as
early as 2 weeks after treatment,
and provide new insight into the
cellular mechanisms underlying dis-
ease improvement following BoNT-A
administration in psoriasis patients.
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TO THE EDITOR
Eczema is caused by complex gene–
environmental interactions. The gene
encoding filaggrin (FLG) on chromo-
some 1q21 reported initially by
genome-wide linkage scan has been
the most consistently replicated one in
Caucasian children (Palmer et al.,
2006; Brown and McLean, 2009). Such
finding was confirmed in a recent meta-
analysis (van den Oord and Sheikh,
2009). Nevertheless, all five known
FLG mutations were rare in our south-
ern Chinese children (Ching et al.,
2009), whereas ethnic-specific FLG
mutations were found in the Japanese
(Nomura et al., 2008), Singaporean
Chinese (Chen et al., 2011), and
Taiwanese (Hsu et al., 2009). A recent
study reported 10 FLG mutations,
which to our knowledge were previously
Table 1. Multi-locus interaction models by GMDR for plasma total IgE
concentration and circulating eosinophil percentage
Combination of SNPs CVC Test accuracy P1
Plasma total IgE concentration
rs2155219 9 0.565 0.0002
rs1933064_rs2155219 10 0.577 o0.0001
rs1933064_rs2155219_rs1892951 6 0.597 o0.0001
rs1933064_rs3862807_rs10793175_rs17135034 2 0.573 0.0016
Circulating eosinophil percentage
rs2155219 10 0.571 0.0006
rs2155219_rs7927894 8 0.575 0.0004
rs1933064_rs2155219_rs17135034 3 0.581 o0.0001
rs11584427_rs2155219_rs7927894_rs10751256 8 0.592 0.0002
Abbreviations: CVC, cross-validation consistency; GMDR, generalized multifactor dimensionality
reduction; SNP, single-nucleotide polymorphism.
1Based on 5,000 permutations.
Abbreviations: eos%, circulating eosinophil percentage; FLG, filaggrin; GMDR, generalized multifactor
dimensionality reduction; GWAS, genome-wide association study; logIgE, logarithm-transformed plasma
total IgE concentration; MAF, minor allele frequency; SNP, single-nucleotide polymorphism
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